Chin Kim, MD
Neuromusculoskeletal Medicine, Sports Medicine · Anaheim, CANPI 1477564607
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 354 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by Amgen at 48.3% of the total.
Across 354 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Novo Nordisk$679
- Exact Sciences$334
- AstraZeneca$315
- Radius Health, Inc.$302
- Bioventus LLC$255
- plus $2K from 27 others
What the payments were for
- Food & beverage$7,132100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 201 | $3,442 |
| Novo Nordisk | 39 | $679 |
| Exact Sciences | 14 | $334 |
| AstraZeneca | 8 | $315 |
| Radius Health, Inc. | 9 | $302 |
| Bioventus LLC | 12 | $255 |
| Boehringer Ingelheim | 2 | $239 |
| Nestle Healthcare Nutrition Inc. | 13 | $237 |
| Pfizer | 8 | $163 |
| Sanofi-aventis U.S. LLC | 3 | $149 |
| Aimmune Therapeutics, Inc. | 7 | $134 |
| Amarin Pharma, Inc. | 6 | $112 |
| Esaote North America, Inc. | 1 | $111 |
| Johnson & Johnson | 3 | $74 |
| Avanos Medical | 4 | $67 |
| Averitas Pharma Inc. | 3 | $66 |
| Boston Scientific | 1 | $50 |
| IBSA Pharma Inc. | 2 | $45 |
| Lundbeck LLC | 2 | $44 |
| Pacira Therapeutics, Inc. | 1 | $35 |
| AbbVie(2 entities) | 2 | $34 |
| Vertiflex, Inc. | 2 | $30 |
| Echosens North America, Inc. | 1 | $29 |
| Vertex | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| Bayer | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Merck | 1 | $12 |
| Polynovo North America LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,132 in reported general payments places this provider in the 85th percentile of 28 neuromusculoskeletal medicine, sports medicine providers in California.
See all neuromusculoskeletal medicine, sports medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 152 | $104,856 |
| CreonLipase/Protease/Amylase | 121 | $94,382 |
| ProliaDenosumab | 56 | $93,973 |
| ZenpepLipase/Protease/Amylase | 53 | $73,077 |
| RybelsusSemaglutide | 57 | $60,078 |
| VascepaIcosapent Ethyl | 185 | $52,601 |
| FarxigaDapagliflozin Propanediol | 73 | $46,984 |
| EliquisApixaban | 48 | $35,938 |
| JardianceEmpagliflozin | 57 | $35,591 |
| Repatha SureclickEvolocumab | 46 | $33,466 |
| OzempicSemaglutide | 19 | $26,272 |
| TrulicityDulaglutide | 23 | $21,954 |
| Oxymorphone Hcl ErOxymorphone Hcl | 12 | $20,275 |
| RestasisCyclosporine | 32 | $16,089 |
| LinzessLinaclotide | 29 | $14,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Restasis, Linzess, Combigan | $34 | $127,826195 claims |
| MerckJanuvia | $12 | $104,856152 claims |
| AmgenProlia | $3,442 | $93,97356 claims |
| Novo NordiskRybelsus, Ozempic | $679 | $86,35076 claims |
| Aimmune Therapeutics, Inc.Zenpep | $134 | $73,07753 claims |
| AstraZenecaFarxiga, Brilinta | $315 | $51,86584 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $239 | $40,74368 claims |
| PfizerEliquis | $163 | $35,93848 claims |
| Lilly USA, LLCTrulicity | $18 | $21,95423 claims |
| Johnson & JohnsonXarelto | $74 | $13,85217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 28 neuromusculoskeletal medicine, sports medicine providers in California.
Other neuromusculoskeletal medicine, sports medicine in Anaheim
- George TangPasadena$95K
- Vahe PanossianPasadena$18K
- Eric SickingerSan Clemente$12K
- Harold JacksonSacramento$3K
- Yigit KarasozenLos Angeles$814
- Thomas ReeceSan Rafael$582
- Michael Bloomvan Nuys$415
- Dirk DiefendorfSan Mateo$404
- Pamela DownsSanta Ana$249
- Gina LoknaSacramento$206
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.